EOH Holdings is now the 100% shareholder of the TCD Group of companies.


TCD attending the ISTH 2017 Congress in Berlin, Germany.

  The Largest International Meeting of the Thrombosis and Hemostasis Community, the ISTH 2017 Congress, is currently taking place at the CityCube/Messe Berlin in Germany. It is the 26th Biennial Congress and will run until Thursday, the 13th of July. The ISTH 2017 Congress is the foremost global meeting in thrombosis, hemostasis and vascular biology. The […]

July 12, 2017 0 comment
TCD joins EOH as the group grows with strategic changes taking effect in May 2017

We are delighted to share the following significant changes and positive developments which took place recently within the TCD Group. New Ownership EOH, a JSE-listed South African based Knowledge Management group, have been in negotiation with the TCD Group since the last quarter of 2015, sharing the strategic objective to expand in the field of […]

May 2, 2017 0 comment
TCD MENA officially registered as CRO in Egypt

We are proud to announce that TCD MENA is now officially registered as a CRO in Egypt. Complementing TCD SA’s long-standing outreach into sub-Saharan and West Africa, TCD MENA was recently established in Heliopolis, Cairo to extend the provision of TCD’s clinical development services to clients looking to conduct research in the Middle East and […]

January 31, 2017 0 comment
Gates Foundation to Invest in HIV Prevention Device

“The Bill & Melinda Gates Foundation is investing as much as $140 million to support development of a tiny implantable drug pump it believes could help prevent people in sub-Saharan Africa and elsewhere from becoming infected with HIV, the virus that causes AIDS. The matchstick-size pump is being developed by Intarcia Therapeutics Inc., a closely […]

December 23, 2016 0 comment
TCD MENA: The family grows

What started one year ago as a dream, became a reality on 1 December 2016 when TCD MENA opened its doors in Heliopolis, Cairo as a full service CRO, serving the Middle-East and North-Africa region. Being part of the TCD Group (www.tcd-global.com), our reach now extends from the Southern tip of the continent, to the […]

December 17, 2016 0 comment
Results from a TCD study : comparing generic Meropenem (Mercide®) with innovator brand (Meronem®)

Triclinium Clinical Development aided in the analysis and reporting of an in-practice study aimed at demonstrating therapeutic and bio-equivalence between a generic brand of meropenem and the innovator. The study demonstrated similar ex vivo efficacy and in vivo pharmacokinetics for the products under observation. Results suggest that the products are clinically interchangeable based on registration […]

December 8, 2016 0 comment
AbbVie pangenotypic combination shows promising results for Hepatitis C

AbbVie is running three large clinical research studies currently where a combination of glecaprevir and pibrentasvir has cured at least 98% of people with hepatitis C. “The results we announced today bring us closer to providing a potential pan-genotypic, once-daily treatment option with 8 weeks of therapy for people living without cirrhosis and who are new […]

November 22, 2016 0 comment
How 3-D printing can save lives in the medical field

For most people the concept of three-dimensional (3D) printing is still seen as something from a science fiction novel, but the medical world is busy embracing this technology and is a major driving force behind its growth. Dr Thomas Bartel, section head of the Heart and Vascular Institute at Cleveland Clinic Abu Dhabi said the following […]

November 18, 2016 0 comment
TB Alliance partners with PepsiCo

TB Alliance is a not-for-profit organisation dedicated to the discovery and development of better, faster-acting, and affordable tuberculosis drugs that are available to those who need them. The organisation recently announced a partnership with beverage company PepsiCo with the sole purpose of improving the taste of treatment for children with TB. “At PepsiCo, we saw […]

November 9, 2016 0 comment
Merck’s new Alzheimer’s drug shows positive results

Merck’s new new Alzheimer’s drug (currently being evaluated in two Phase 3 clinical trials) has shown positive results in targeting the most visible sign of the disease in the patient’s brain. These results have had a very positive impact on the patient community suffering from Alzheimer’s as this could possibly be the first new treatment for the […]

November 4, 2016 0 comment